Switzerland's Sandoz expects rapid mid-term growth
08/09/2026 06:20
Switzerland's Sandoz expects rapid mid-term growth ZURICH, Sept 8 (Reuters) - Swiss generic drug maker Sandoz SDZ.S is aiming to more than double its net sales from 2025 to 2035, the company said on Tuesday at its capital markets day.
Sandoz said it is now also targeting annual net sales growth at a mid-to-high single-digit rate at constant currencies from 2025 to 2030 as it outlined its Bio100 biosimilars strategy that banks on its biosimilars drug pipeline.
(Reporting by Marleen Kaesebier)
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant